
UroGen Pharma Reports Promising Phase 1 Dose-Escalation Study Results for UGN-301 in Non-Muscle Invasive Bladder Cancer
UroGen Pharma Announces Promising Early Results from Phase 1 Study Evaluating UGN-301 for Non-Muscle Invasive Bladder Cancer UroGen Pharma Ltd. (Nasdaq: URGN), a biotechnology company committed to developing and commercializing innovative therapies for urothelial and specialty cancers, today announced positive…












